Martha Henao, MD
Retina Specialist · Upland, CANPI 1316358971
Payments from drug & device makers
Across 88 payments — averaging $42.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Regeneron$806
- Genentech USA, Inc.$517
- Regeneron Healthcare Solutions, Inc.$511
- Amgen$359
- Apellis Pharmaceuticals, Inc.$299
- AbbVie$277
- plus $932 from 10 others
Across 8 payments — averaging $195.80 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Regeneron$2K
What the payments were for
- Travel & lodging$80622%
- Food & beverage$2,89578%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Regeneron | 2 | $806 |
| Genentech USA, Inc. | 15 | $517 |
| Regeneron Healthcare Solutions, Inc. | 12 | $511 |
| Amgen(2 entities) | 9 | $359 |
| Apellis Pharmaceuticals, Inc. | 4 | $299 |
| AbbVie(2 entities) | 12 | $277 |
| ANI Pharmaceuticals, Inc. | 7 | $243 |
| Astellas Pharma US Inc | 9 | $170 |
| Aerie Pharmaceuticals, Inc. | 3 | $150 |
| Harrow Eye, LLC | 2 | $113 |
| Sun Pharmaceutical Industries Inc. | 5 | $92 |
| Novartis | 3 | $50 |
| Alcon | 2 | $45 |
| Biogen | 1 | $29 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 1 | $22 |
| Boston Scientific | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,702 in reported general payments places this provider in the 45th percentile of 187 retina specialist providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Cyclosporine | 11 | $3,481 |
| Prednisolone Acetate | 51 | $2,272 |
| Atropine Sulfate | 31 | $1,216 |
| Ofloxacin | 41 | $456 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 23 | $371 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 21 | $253 |
| Azelastine Hcl | 13 | $240 |
| Acetaminophen-CodeineAcetaminophen With Codeine | 11 | $66 |
Paid to pharmacies, not to this prescriber.
Other retina specialist in Upland
- Dante PieramiciSanta Barbara$15.1M
- Margaret ChangSacramento$13.2M
- Hani Salehi-HadHuntington Beach$12.2M
- Payam AminiPasadena$9.9M
- Joel PearlmanSacramento$8.3M
- Dilsher DhootSanta Barbara$8.2M
- Ashkan PirouzFullerton$6.9M
- Roger GoldbergWalnut Creek$5M
- Sean AdreanFullerton$2.9M
- Nathan SteinleSanta Barbara$2.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.